000724077 000__ 03080cam\a2200469Ii\4500
000724077 001__ 724077
000724077 005__ 20230306140418.0
000724077 006__ m\\\\\o\\d\\\\\\\\
000724077 007__ cr\cn\nnnunnun
000724077 008__ 141105t20142015nyua\\\\o\\\\\001\0\eng\d
000724077 020__ $$a9781493913992$$qelectronic book
000724077 020__ $$a1493913999$$qelectronic book
000724077 020__ $$z9781493913985
000724077 035__ $$aSP(OCoLC)ocn894509554
000724077 035__ $$aSP(OCoLC)894509554
000724077 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dOCLCF$$dUWO$$dIDEBK$$dEBLCP$$dCDX
000724077 049__ $$aISEA
000724077 050_4 $$aRM301.25
000724077 08204 $$a615.19$$223
000724077 24500 $$aDiscovering and developing molecules with optimal drug-like properties$$h[electronic resource] /$$cAllen C. Templeton, Stephen R. Byrn, Roy J. Haskell, Thomas E. Prisinzano, editors.
000724077 264_1 $$aNew York :$$bSpringer,$$c[2014]
000724077 264_4 $$c©2015
000724077 300__ $$a1 online resource (xi, 511 pages) :$$billustrations (some color).
000724077 336__ $$atext$$btxt$$2rdacontent
000724077 337__ $$acomputer$$bc$$2rdamedia
000724077 338__ $$aonline resource$$bcr$$2rdacarrier
000724077 4901_ $$aAPS advances in the pharmaceutical sciences series
000724077 500__ $$aIncludes index.
000724077 506__ $$aAccess limited to authorized users.
000724077 520__ $$aThis authoritative volume provides a contemporary view on the latest research in molecules with optimal drug-like properties. It is a valuable source to access current best practices as well as new research techniques and strategies. Written by leading scientists in their fields, the text consists of fourteen chapters with an underlying theme of early collaborative opportunities between pharmaceutical and discovery sciences. The book explores the practical realities of performing physical pharmaceutical and biopharmaceutical research in the context of drug discovery with short timelines and low compound availability. Chapters cover strategies and tactics to enable discovery as well as predictive approaches to establish, understand and communicate risks in early development. It also examines the detection, characterization and assessment of risks on the solid state properties of advanced discovery and early development candidates, highlighting the link between solid state properties and critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on linking physiochemical properties of molecules to formulation selection in preclinical and clinical settings.
000724077 588__ $$aOnline resource; title from PDF title page (viewed November 13, 2014).
000724077 650_0 $$aDrugs$$xResearch.
000724077 650_0 $$aDrugs$$xDesign.
000724077 7001_ $$aTempleton, Allen C.,$$eeditor.
000724077 7001_ $$aByrn, Stephen R.,$$eeditor.
000724077 7001_ $$aHaskell, Roy J.,$$eeditor.
000724077 7001_ $$aPrisinzano, Thomas E.,$$eeditor.
000724077 830_0 $$aAAPS advances in the pharmaceutical sciences series.
000724077 852__ $$bebk
000724077 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-1-4939-1399-2$$zOnline Access$$91397441.1
000724077 909CO $$ooai:library.usi.edu:724077$$pGLOBAL_SET
000724077 980__ $$aEBOOK
000724077 980__ $$aBIB
000724077 982__ $$aEbook
000724077 983__ $$aOnline
000724077 994__ $$a92$$bISE